Is Medpace Holdings Stock Halal?

Is Medpace Holdings Stock Halal?

How much of Medpace Holdings’ revenue comes from haram?

Medpace is a clinical contract research organization that provides services for the biotechnology, pharmaceutical, and medical device industries.

Medpace earns its revenue from the following revenue sources:

Medpace’s primary source of income is generated from research contracts. The company conducts clinical testing and research in the fields listed below.

  • Oncology
  • Metabolic
  • Antiviral and Anti-infective (AVAI)
  • Cardiology
  • Central Nervous System
  • Other Therapeutic Areas

The contributions from each of Medpace Holdings’ revenue segments in their 2020 annual report were as follows:

Practical Islamic Finance concludes:

None of Medpace Holdings’ revenue comes from anything inherently haram.

Does Medpace Holdings rely on interest to operate?

for period ended
Fiscal year
Fiscal year
Interest Income (Net) $307
Total Revenue$538,258$925,925$860,969
Interest Expense (Net)$41$1,568
Total Expenses$448,211$758,883$733,706
Interest Income / Revenue0.03%
Interest Expense / Total Expense0.01%0.21%
*Numbers in thousands, U.S. dollars

Practical Islamic Finance concludes:

Riba is used but not relied upon in Medpace Holdings’ operations.

What is Medpace Holdings’ Environmental, Social, and Governance (ESG) impact?


No notable environmental highlights.


Medpace has a Glassdoor rating of 3.1 out of 5.0 from over 680 current and previous employees compared to a 3.3 average for all other Glassdoor rated companies.


No notable governance highlights.

Practical Islamic Finance concludes:

Medpace Holdings has a net positive ESG impact.

Comfort Rating

From Medpace Holdings’ business, financial, and ESG reviews, Practical Islamic Finance rates Medpace Holdings stock as:

Comfortable to invest in from a Halal perspective.


Medpace 2020 10-K

Medpace Q2 2021 10-Q

Medpace Sustainability

Medpace Reviews

Subscribe to get our “Intro to Halal-Conscious Investing” and much more for FREE!

Enter your email address to subscribe:*